
WHO's Shift: GLP-1 Drugs Transform Obesity Treatment
The WHO has issued landmark guidelines endorsing GLP-1 receptor agonists for obesity treatment, marking a pivotal shift from lifestyle-only approaches. These drugs, including semaglutide and tirzepatide, offer substantial weight loss but come with cautions on long-term safety. This guide unpacks the science, evidence, and practical implications for patients.







